Take a bite out of
G-CSF acquisition costs*
*Based on wholesale acquisition cost (WAC) of all short-acting G-CSF products as of November 11, 2013. WAC represents published
catalogue or list prices and may not represent actual transactional prices. Please contact your supplier for actual prices.
Indication
» GRANIXTM (tbo-filgrastim) Injection is a leukocyte growth factor indicated for reduction
in the duration of severe neutropenia in patients with nonmyeloid malignancies receiving
myelosuppressive anticancer drugs associated with a clinically significant incidence
of febrile neutropenia.
Important Safety Information
» Splenic rupture: Splenic rupture, including fatal cases, can occur following the administration
of human granulocyte colony-stimulating factors (hG-CSFs). Discontinue GRANIX and evaluate
for an enlarged spleen or splenic rupture in patients who report upper abdominal or shoulder
pain after receiving GRANIX.
» Acute respiratory distress syndrome (ARDS): ARDS can occur in patients receiving hG-CSFs.
Evaluate patients who develop fever and lung infiltrates or respiratory distress after receiving
GRANIX, for ARDS. Discontinue GRANIX in patients with ARDS.
» Allergic reactions: Serious allergic reactions, including anaphylaxis, can occur in patients receiving
hG-CSFs. Reactions can occur on initial exposure. Permanently discontinue GRANIX in patients with
serious allergic reactions. Do not administer GRANIX to patients with a history of serious allergic
reactions to filgrastim or pegfilgrastim.